Supreme Court Abstains From Drugs: Will Not Review J&J Vs. Abbott; Takes No Action On Gene Patents
This article was originally published in The Pink Sheet Daily
Executive Summary
The high court denied J&J’s request for review of a Federal Circuit decision that overturned a $1.67 billion jury verdict against Abbott’s Humira; it made no decision on ACLU’s petition for review of Myriad Genetics’ BRCA gene patents.
You may also be interested in...
Supreme Court Overturns Personalized Medicine Patents, Creating Confusion In Diagnostics Realm
High court rules the processes covered by two patents to determine proper drug dosages based on metabolite concentrations do not transform unpatentable natural laws into patent-eligible applications.
Supreme Court Overturns Drug Calibration Patents, Creating Confusion In Biotech Realm
The court’s finding that Prometheus’ drug calibration test is unpatentable has left the biotech community reeling with uncertainty as to whether method of treatment claims, particularly those involving biomarkers, will be patent eligible.
Drug Calibration Patents Under Scrutiny As Supreme Court Weighs How To Build On Law Of Nature
During oral arguments in Mayo v. Prometheus, justices question what standard to apply in assessing whether the correlation of a drug’s metabolites to proper dosage is patentable; ACLU petitions court to review Myriad gene patent case.